AcuCort signs its first commercial agreement for the company's drug Zeqmelit™
- Written by PR Newswire
LUND, Sweden, Nov. 24, 2022 /PRNewswire/ -- AcuCort AB (publ) (Spotlight Stock Market: ACUC) today announces that the company has signed an exclusive commercial agreement with the global biopharmaceutical company Kamada Ltd., (NASDAQ: KMDA; TASE: KMDA.TA). The agreement gives Kamada the exclusive right to the marketing and sales as well as...
Read more: AcuCort signs its first commercial agreement for the company's drug Zeqmelit™














